On April 22, 2020, Italfarmaco joined Parent Project Muscular Dystrophy for a webinar to update the community about Italfarmaco’s development of Givinostat and the recent results of the futility analysis of the enrolling Phase 3 confirmatory study in Duchenne muscular dystrophy.